SLFN11 and cancer: Because SLFN11 (Schlafen 11) expression in cancer cells has been reported to determine their sensitivity to a wide range of DNA-damaging anticancer drugs, including topoisomerase, PARP inhibitors, and platinum-based drugs (50), we examined SLFN11 expression in theACC cell lines and surgical samples.